Laura Saba
Concepts (700)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Stenosis | 8 | 2020 | 102 | 3.390 |
Why?
| | Plaque, Atherosclerotic | 4 | 2020 | 60 | 2.260 |
Why?
| | Alcohol Drinking | 18 | 2021 | 826 | 1.820 |
Why?
| | Quantitative Trait Loci | 25 | 2025 | 374 | 1.740 |
Why?
| | Carotid Arteries | 5 | 2020 | 207 | 1.540 |
Why?
| | Adrenocortical Carcinoma | 8 | 2026 | 67 | 1.350 |
Why?
| | Transcriptome | 10 | 2025 | 1045 | 1.340 |
Why?
| | Ethanol | 16 | 2024 | 627 | 1.310 |
Why?
| | Brain | 23 | 2026 | 2933 | 1.280 |
Why?
| | Adrenal Cortex Neoplasms | 7 | 2026 | 65 | 1.230 |
Why?
| | Gene Regulatory Networks | 7 | 2023 | 318 | 1.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2024 | 549 | 1.050 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 214 | 1.020 |
Why?
| | Quantitative Trait, Heritable | 7 | 2017 | 118 | 0.990 |
Why?
| | Gene Expression Profiling | 16 | 2021 | 1782 | 0.960 |
Why?
| | Magnetic Resonance Imaging | 7 | 2025 | 3863 | 0.900 |
Why?
| | Rats, Inbred Strains | 7 | 2019 | 321 | 0.900 |
Why?
| | Mitotane | 6 | 2025 | 10 | 0.850 |
Why?
| | Systems Biology | 3 | 2021 | 72 | 0.840 |
Why?
| | Myocarditis | 1 | 2025 | 102 | 0.830 |
Why?
| | Rats | 24 | 2026 | 5597 | 0.820 |
Why?
| | Trace Elements | 2 | 2021 | 52 | 0.810 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2023 | 3 | 0.800 |
Why?
| | Hemorrhage | 2 | 2019 | 809 | 0.780 |
Why?
| | Genetic Predisposition to Disease | 13 | 2024 | 2363 | 0.760 |
Why?
| | Liver | 10 | 2024 | 1887 | 0.750 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 103 | 0.740 |
Why?
| | MicroRNAs | 6 | 2019 | 701 | 0.700 |
Why?
| | Atrial Appendage | 1 | 2022 | 35 | 0.690 |
Why?
| | Phenotype | 16 | 2026 | 3162 | 0.680 |
Why?
| | Polymorphism, Single Nucleotide | 18 | 2025 | 2145 | 0.670 |
Why?
| | Sequence Analysis, RNA | 7 | 2022 | 442 | 0.670 |
Why?
| | Animals | 65 | 2026 | 38058 | 0.670 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.660 |
Why?
| | Polyadenylation | 1 | 2021 | 41 | 0.650 |
Why?
| | Protein Carbonylation | 7 | 2019 | 57 | 0.640 |
Why?
| | RNA | 6 | 2021 | 940 | 0.640 |
Why?
| | RNA, Long Noncoding | 2 | 2020 | 177 | 0.630 |
Why?
| | Liver Diseases, Alcoholic | 5 | 2024 | 97 | 0.620 |
Why?
| | Atherosclerosis | 2 | 2021 | 409 | 0.610 |
Why?
| | Alcoholism | 9 | 2026 | 817 | 0.600 |
Why?
| | Mustard Gas | 3 | 2025 | 93 | 0.590 |
Why?
| | Chemical Warfare Agents | 3 | 2025 | 104 | 0.590 |
Why?
| | Adipose Tissue | 2 | 2020 | 652 | 0.580 |
Why?
| | Software | 8 | 2025 | 690 | 0.570 |
Why?
| | Drug Tolerance | 4 | 2020 | 100 | 0.570 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 120 | 0.570 |
Why?
| | Male | 80 | 2026 | 72315 | 0.550 |
Why?
| | Tunica Media | 1 | 2018 | 37 | 0.540 |
Why?
| | Tunica Intima | 1 | 2018 | 79 | 0.530 |
Why?
| | Genetic Variation | 5 | 2024 | 983 | 0.530 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2025 | 194 | 0.530 |
Why?
| | Databases, Genetic | 5 | 2017 | 248 | 0.520 |
Why?
| | Complement C3 | 5 | 2024 | 191 | 0.510 |
Why?
| | Alcohol-Related Disorders | 1 | 2018 | 120 | 0.510 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1406 | 0.500 |
Why?
| | Humans | 102 | 2026 | 144759 | 0.500 |
Why?
| | Middle Aged | 46 | 2025 | 35875 | 0.500 |
Why?
| | Tomography, X-Ray Computed | 8 | 2021 | 2730 | 0.490 |
Why?
| | Dexamethasone | 4 | 2025 | 372 | 0.490 |
Why?
| | Female | 75 | 2026 | 78271 | 0.470 |
Why?
| | beta-Thalassemia | 5 | 2025 | 40 | 0.470 |
Why?
| | Genomics | 6 | 2024 | 834 | 0.460 |
Why?
| | Brain Ischemia | 1 | 2019 | 358 | 0.460 |
Why?
| | Central Nervous System Depressants | 4 | 2010 | 83 | 0.450 |
Why?
| | Aged | 30 | 2024 | 25913 | 0.440 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2026 | 120 | 0.430 |
Why?
| | Retrospective Studies | 19 | 2025 | 17066 | 0.430 |
Why?
| | Angiography | 4 | 2010 | 208 | 0.420 |
Why?
| | Computed Tomography Angiography | 3 | 2021 | 145 | 0.420 |
Why?
| | Corneal Injuries | 2 | 2025 | 42 | 0.420 |
Why?
| | Models, Statistical | 1 | 2018 | 681 | 0.410 |
Why?
| | Aged, 80 and over | 13 | 2024 | 8265 | 0.400 |
Why?
| | Internet | 6 | 2010 | 699 | 0.390 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2019 | 758 | 0.380 |
Why?
| | Complement Activation | 4 | 2025 | 411 | 0.380 |
Why?
| | Mice | 34 | 2025 | 18339 | 0.380 |
Why?
| | Bayes Theorem | 5 | 2020 | 433 | 0.370 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 74 | 0.360 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2925 | 0.360 |
Why?
| | Genome | 4 | 2024 | 306 | 0.340 |
Why?
| | Adult | 43 | 2025 | 40449 | 0.340 |
Why?
| | Oxidative Stress | 7 | 2026 | 1339 | 0.330 |
Why?
| | Heart Ventricles | 2 | 2026 | 760 | 0.330 |
Why?
| | Ultrasonography | 3 | 2020 | 770 | 0.330 |
Why?
| | Aldehydes | 5 | 2019 | 142 | 0.330 |
Why?
| | Glutathione Transferase | 4 | 2019 | 100 | 0.320 |
Why?
| | Mice, Inbred Strains | 9 | 2020 | 397 | 0.320 |
Why?
| | Health Education | 3 | 2008 | 358 | 0.300 |
Why?
| | ROC Curve | 4 | 2019 | 614 | 0.300 |
Why?
| | Endometriosis | 2 | 2020 | 57 | 0.290 |
Why?
| | Rats, Wistar | 3 | 2020 | 451 | 0.290 |
Why?
| | Carotid Artery Diseases | 1 | 2009 | 69 | 0.290 |
Why?
| | Genetic Association Studies | 5 | 2017 | 372 | 0.290 |
Why?
| | Oxycodone | 2 | 2026 | 53 | 0.280 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 30 | 0.280 |
Why?
| | Synaptic Transmission | 1 | 2010 | 290 | 0.280 |
Why?
| | Models, Genetic | 6 | 2025 | 536 | 0.270 |
Why?
| | Brain Diseases | 1 | 2009 | 152 | 0.270 |
Why?
| | Nanoparticles | 4 | 2025 | 519 | 0.270 |
Why?
| | Gastrointestinal Microbiome | 2 | 2026 | 771 | 0.260 |
Why?
| | Cornea | 2 | 2025 | 155 | 0.250 |
Why?
| | Genotype | 11 | 2025 | 1833 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 5 | 2024 | 576 | 0.250 |
Why?
| | Point Mutation | 2 | 2001 | 243 | 0.250 |
Why?
| | Contrast Media | 5 | 2021 | 488 | 0.240 |
Why?
| | Polyploidy | 1 | 2026 | 15 | 0.240 |
Why?
| | Genes, Regulator | 1 | 2006 | 35 | 0.240 |
Why?
| | Genetic Background | 1 | 2026 | 16 | 0.240 |
Why?
| | Receptors, GABA-A | 3 | 2026 | 138 | 0.240 |
Why?
| | Breast Neoplasms | 6 | 2023 | 2452 | 0.240 |
Why?
| | Triterpenes | 1 | 2026 | 25 | 0.240 |
Why?
| | Adenylyl Cyclases | 3 | 2012 | 60 | 0.230 |
Why?
| | PTEN Phosphohydrolase | 2 | 2018 | 164 | 0.230 |
Why?
| | Gene Expression Regulation | 8 | 2025 | 2608 | 0.230 |
Why?
| | Smoking Prevention | 1 | 2006 | 166 | 0.230 |
Why?
| | Microfilament Proteins | 1 | 2026 | 135 | 0.230 |
Why?
| | Activating Transcription Factor 3 | 1 | 2025 | 5 | 0.220 |
Why?
| | Rats, Inbred SHR | 4 | 2018 | 37 | 0.220 |
Why?
| | Activating Transcription Factor 4 | 1 | 2025 | 22 | 0.220 |
Why?
| | Limbus Corneae | 1 | 2025 | 8 | 0.220 |
Why?
| | Iron | 2 | 2021 | 359 | 0.220 |
Why?
| | Phytochemicals | 1 | 2025 | 13 | 0.220 |
Why?
| | Recombination, Genetic | 2 | 2017 | 205 | 0.220 |
Why?
| | Tea | 1 | 2025 | 17 | 0.220 |
Why?
| | Nanomedicine | 1 | 2025 | 46 | 0.220 |
Why?
| | Hypothalamo-Hypophyseal System | 4 | 2017 | 198 | 0.220 |
Why?
| | Signal Transduction | 10 | 2026 | 5226 | 0.220 |
Why?
| | Polyethylene Glycols | 3 | 2025 | 654 | 0.210 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5992 | 0.210 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 165 | 0.210 |
Why?
| | Endarterectomy, Carotid | 2 | 2017 | 60 | 0.210 |
Why?
| | Heart Transplantation | 2 | 2021 | 736 | 0.210 |
Why?
| | Doxorubicin | 3 | 2025 | 397 | 0.200 |
Why?
| | Stents | 1 | 2008 | 556 | 0.200 |
Why?
| | Algorithms | 4 | 2023 | 1837 | 0.200 |
Why?
| | Magnesium | 2 | 2021 | 155 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2026 | 1143 | 0.200 |
Why?
| | Cysteine | 1 | 2024 | 210 | 0.200 |
Why?
| | Base Sequence | 6 | 2021 | 2190 | 0.200 |
Why?
| | Gastrointestinal Tract | 1 | 2026 | 208 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2024 | 172 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.190 |
Why?
| | Diastole | 1 | 2023 | 143 | 0.190 |
Why?
| | Immunoglobulins | 2 | 2024 | 160 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1985 | 0.190 |
Why?
| | Rats, Inbred BN | 3 | 2018 | 55 | 0.180 |
Why?
| | Lysine | 1 | 2024 | 302 | 0.180 |
Why?
| | Dextrans | 2 | 2024 | 86 | 0.180 |
Why?
| | Acute Disease | 1 | 2025 | 1030 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2023 | 132 | 0.180 |
Why?
| | Whole Genome Sequencing | 2 | 2024 | 182 | 0.180 |
Why?
| | Phosphorus | 2 | 2021 | 99 | 0.180 |
Why?
| | Fetal Development | 2 | 2022 | 299 | 0.180 |
Why?
| | Behavior, Addictive | 2 | 2020 | 88 | 0.170 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 202 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2026 | 556 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 21 | 0.170 |
Why?
| | Proteome | 3 | 2024 | 518 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 474 | 0.170 |
Why?
| | Heart Atria | 1 | 2022 | 144 | 0.170 |
Why?
| | Magnesium Deficiency | 1 | 2020 | 2 | 0.170 |
Why?
| | Chromatography, Liquid | 5 | 2024 | 454 | 0.170 |
Why?
| | Selenium | 1 | 2021 | 49 | 0.170 |
Why?
| | Myocardium | 2 | 2018 | 939 | 0.170 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2021 | 139 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 120 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2024 | 477 | 0.160 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 98 | 0.160 |
Why?
| | Copper | 1 | 2021 | 113 | 0.160 |
Why?
| | Hydroxycholesterols | 1 | 2020 | 5 | 0.160 |
Why?
| | Stem Cells | 1 | 2025 | 626 | 0.160 |
Why?
| | Echocardiography | 1 | 2023 | 652 | 0.160 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 15 | 0.160 |
Why?
| | Complement System Proteins | 2 | 2024 | 316 | 0.160 |
Why?
| | Iron Overload | 2 | 2025 | 19 | 0.160 |
Why?
| | Sigmoid Diseases | 1 | 2020 | 14 | 0.160 |
Why?
| | Rectal Diseases | 1 | 2020 | 22 | 0.160 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2019 | 9 | 0.160 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2019 | 23 | 0.160 |
Why?
| | Osteoprotegerin | 3 | 2009 | 22 | 0.150 |
Why?
| | Risk | 2 | 2021 | 911 | 0.150 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 41 | 0.150 |
Why?
| | User-Computer Interface | 1 | 2020 | 164 | 0.150 |
Why?
| | Genetic Markers | 1 | 2020 | 331 | 0.150 |
Why?
| | Rabbits | 3 | 2025 | 648 | 0.150 |
Why?
| | Pancreatic Diseases | 1 | 2020 | 66 | 0.150 |
Why?
| | Pesticides | 1 | 2019 | 63 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 630 | 0.150 |
Why?
| | Anthracenes | 1 | 2019 | 31 | 0.150 |
Why?
| | Drosophila | 1 | 2020 | 166 | 0.150 |
Why?
| | Gene Expression | 3 | 2014 | 1490 | 0.150 |
Why?
| | Reflex, Righting | 2 | 2018 | 15 | 0.150 |
Why?
| | Protein Corona | 1 | 2019 | 6 | 0.150 |
Why?
| | Mice, Inbred DBA | 5 | 2019 | 187 | 0.150 |
Why?
| | Opsonin Proteins | 1 | 2019 | 19 | 0.150 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.150 |
Why?
| | Liposomes | 2 | 2019 | 250 | 0.150 |
Why?
| | Cushing Syndrome | 2 | 2010 | 10 | 0.150 |
Why?
| | Biomarkers | 7 | 2020 | 4271 | 0.140 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.140 |
Why?
| | Fluorenes | 1 | 2019 | 46 | 0.140 |
Why?
| | Chimera | 1 | 2019 | 61 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.140 |
Why?
| | Learning Curve | 1 | 2019 | 70 | 0.140 |
Why?
| | Antioxidants | 2 | 2019 | 549 | 0.140 |
Why?
| | Drosophila Proteins | 1 | 2020 | 212 | 0.140 |
Why?
| | Steroid 11-beta-Hydroxylase | 1 | 2018 | 2 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2026 | 2194 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 244 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3409 | 0.140 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 114 | 0.140 |
Why?
| | Lymphocytes | 1 | 2020 | 382 | 0.140 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 22 | 0.140 |
Why?
| | Sex Characteristics | 4 | 2021 | 790 | 0.140 |
Why?
| | Hallucinogens | 1 | 2020 | 108 | 0.140 |
Why?
| | Apoptosis | 3 | 2026 | 2430 | 0.140 |
Why?
| | Cell Degranulation | 1 | 2018 | 42 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 120 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 276 | 0.140 |
Why?
| | Zinc | 1 | 2021 | 295 | 0.140 |
Why?
| | Angiography, Digital Subtraction | 1 | 2018 | 48 | 0.130 |
Why?
| | Silver | 1 | 2018 | 38 | 0.130 |
Why?
| | Smoking | 2 | 2020 | 1472 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 116 | 0.130 |
Why?
| | Hippocampus | 2 | 2022 | 965 | 0.130 |
Why?
| | Receptors, Nicotinic | 1 | 2020 | 321 | 0.130 |
Why?
| | Graft Rejection | 1 | 2021 | 540 | 0.130 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 246 | 0.130 |
Why?
| | Food Preferences | 2 | 2009 | 126 | 0.130 |
Why?
| | Ferrosoferric Oxide | 1 | 2017 | 25 | 0.130 |
Why?
| | Lung | 2 | 2021 | 4109 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1095 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2018 | 95 | 0.130 |
Why?
| | Hepatitis | 1 | 2017 | 43 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.130 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 59 | 0.130 |
Why?
| | Computational Biology | 3 | 2017 | 680 | 0.130 |
Why?
| | Interleukin-6 | 3 | 2006 | 780 | 0.130 |
Why?
| | Pancreas | 1 | 2020 | 341 | 0.130 |
Why?
| | Risk Factors | 6 | 2019 | 10779 | 0.130 |
Why?
| | Disease Models, Animal | 7 | 2025 | 4557 | 0.130 |
Why?
| | Web Browser | 1 | 2017 | 14 | 0.130 |
Why?
| | Gynecology | 1 | 2019 | 178 | 0.130 |
Why?
| | Models, Animal | 1 | 2019 | 392 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1455 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 660 | 0.130 |
Why?
| | Globins | 2 | 1997 | 21 | 0.120 |
Why?
| | Lod Score | 1 | 2016 | 62 | 0.120 |
Why?
| | Mast Cells | 1 | 2018 | 146 | 0.120 |
Why?
| | Cholestasis | 1 | 2019 | 219 | 0.120 |
Why?
| | Gene Ontology | 1 | 2016 | 53 | 0.120 |
Why?
| | Pain Threshold | 2 | 2010 | 73 | 0.120 |
Why?
| | Chromosomes, Mammalian | 1 | 2016 | 28 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2016 | 11 | 0.120 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2016 | 14 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2016 | 21 | 0.120 |
Why?
| | Calcium | 2 | 2021 | 1183 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 94 | 0.120 |
Why?
| | Liver Diseases | 1 | 2019 | 304 | 0.120 |
Why?
| | Choice Behavior | 2 | 2014 | 177 | 0.120 |
Why?
| | Seizures | 1 | 2020 | 460 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3540 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 216 | 0.120 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2015 | 19 | 0.120 |
Why?
| | von Willebrand Factor | 1 | 2016 | 85 | 0.120 |
Why?
| | Mitochondria | 2 | 2021 | 984 | 0.120 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 246 | 0.120 |
Why?
| | Consensus | 1 | 2018 | 488 | 0.110 |
Why?
| | beta Karyopherins | 1 | 2015 | 9 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2024 | 600 | 0.110 |
Why?
| | Hydrocortisone | 4 | 2012 | 304 | 0.110 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 39 | 0.110 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 36 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 767 | 0.110 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 84 | 0.110 |
Why?
| | Anxiety | 1 | 2022 | 1109 | 0.110 |
Why?
| | Immune System | 1 | 2016 | 179 | 0.110 |
Why?
| | Darkness | 1 | 2015 | 26 | 0.110 |
Why?
| | Allergens | 1 | 2018 | 384 | 0.110 |
Why?
| | Pulmonary Artery | 1 | 2021 | 1134 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 442 | 0.110 |
Why?
| | Diet | 3 | 2008 | 1273 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 995 | 0.110 |
Why?
| | Circadian Rhythm | 2 | 2020 | 514 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 266 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1134 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 534 | 0.100 |
Why?
| | Mammography | 2 | 2006 | 166 | 0.100 |
Why?
| | Species Specificity | 4 | 2014 | 574 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2018 | 2496 | 0.100 |
Why?
| | Early Detection of Cancer | 2 | 2023 | 463 | 0.100 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2013 | 6 | 0.100 |
Why?
| | Chloride Channels | 1 | 1993 | 34 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2017 | 627 | 0.100 |
Why?
| | Oxidation-Reduction | 3 | 2024 | 1087 | 0.100 |
Why?
| | Proteomics | 4 | 2024 | 1195 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 262 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2009 | 535 | 0.100 |
Why?
| | Chromosome Mapping | 4 | 2020 | 510 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1125 | 0.100 |
Why?
| | Genes | 1 | 1993 | 226 | 0.100 |
Why?
| | Database Management Systems | 2 | 2017 | 50 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2020 | 888 | 0.100 |
Why?
| | Blood Pressure | 1 | 2020 | 1769 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1256 | 0.100 |
Why?
| | Cannabis | 1 | 2020 | 509 | 0.100 |
Why?
| | Cross-Sectional Studies | 6 | 2025 | 5868 | 0.100 |
Why?
| | Mice, Knockout | 5 | 2019 | 3121 | 0.090 |
Why?
| | Catalase | 2 | 2017 | 130 | 0.090 |
Why?
| | Exercise | 3 | 2014 | 2201 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 583 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1137 | 0.090 |
Why?
| | Dogs | 2 | 2025 | 437 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2001 | 406 | 0.090 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2012 | 91 | 0.090 |
Why?
| | Feces | 2 | 2026 | 513 | 0.090 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2012 | 40 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2011 | 25 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5408 | 0.090 |
Why?
| | Metabolomics | 3 | 2025 | 727 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 370 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1496 | 0.090 |
Why?
| | Hypertension | 1 | 2020 | 1263 | 0.080 |
Why?
| | Kidney | 1 | 2019 | 1495 | 0.080 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2010 | 17 | 0.080 |
Why?
| | Rats, Long-Evans | 2 | 2021 | 125 | 0.080 |
Why?
| | Receptors, GABA | 1 | 2010 | 13 | 0.080 |
Why?
| | Area Under Curve | 3 | 2019 | 330 | 0.080 |
Why?
| | Pituitary-Adrenal Function Tests | 1 | 2010 | 3 | 0.080 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 428 | 0.080 |
Why?
| | Bone Density | 2 | 2012 | 482 | 0.080 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 285 | 0.080 |
Why?
| | Inflammation | 4 | 2025 | 2878 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1253 | 0.080 |
Why?
| | Colonic Diseases, Functional | 2 | 2000 | 3 | 0.080 |
Why?
| | Camptothecin | 2 | 2023 | 140 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 570 | 0.080 |
Why?
| | RNA, Messenger | 5 | 2018 | 2832 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 928 | 0.080 |
Why?
| | Postmenopause | 1 | 2012 | 391 | 0.080 |
Why?
| | Italy | 4 | 2019 | 113 | 0.080 |
Why?
| | Logistic Models | 3 | 2010 | 2117 | 0.070 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2009 | 11 | 0.070 |
Why?
| | Morphine | 1 | 2010 | 168 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1953 | 0.070 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2930 | 0.070 |
Why?
| | United States | 4 | 2022 | 15966 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2010 | 192 | 0.070 |
Why?
| | Neoplasms | 2 | 2022 | 2875 | 0.070 |
Why?
| | NF-kappa B | 2 | 2025 | 661 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2024 | 509 | 0.070 |
Why?
| | Cyclooxygenase 2 | 2 | 2019 | 165 | 0.070 |
Why?
| | RANK Ligand | 1 | 2008 | 26 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 780 | 0.070 |
Why?
| | Iohexol | 1 | 2008 | 23 | 0.070 |
Why?
| | Aorta, Abdominal | 1 | 2008 | 52 | 0.070 |
Why?
| | Radiographic Image Enhancement | 1 | 2008 | 57 | 0.070 |
Why?
| | Breeding | 2 | 2014 | 63 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 400 | 0.070 |
Why?
| | Receptors, Glucocorticoid | 1 | 2009 | 138 | 0.070 |
Why?
| | Young Adult | 6 | 2024 | 14105 | 0.070 |
Why?
| | Androgens | 1 | 2009 | 186 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 123 | 0.070 |
Why?
| | Alanine Transaminase | 2 | 2019 | 151 | 0.070 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2007 | 55 | 0.070 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2017 | 147 | 0.070 |
Why?
| | Vagina | 2 | 2020 | 201 | 0.070 |
Why?
| | Computer-Assisted Instruction | 1 | 2008 | 71 | 0.060 |
Why?
| | Electronic Mail | 1 | 2007 | 61 | 0.060 |
Why?
| | Observer Variation | 1 | 2008 | 355 | 0.060 |
Why?
| | Mutation | 3 | 2017 | 4089 | 0.060 |
Why?
| | Hepatic Encephalopathy | 1 | 2007 | 25 | 0.060 |
Why?
| | Membrane Proteins | 1 | 1993 | 1166 | 0.060 |
Why?
| | Alcohol Dehydrogenase | 1 | 2006 | 16 | 0.060 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2008 | 167 | 0.060 |
Why?
| | Adrenal Cortex | 1 | 2006 | 33 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2012 | 586 | 0.060 |
Why?
| | Superoxide Dismutase | 2 | 2019 | 301 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2006 | 10 | 0.060 |
Why?
| | Adolescent | 8 | 2020 | 22428 | 0.060 |
Why?
| | Cecum | 1 | 2026 | 37 | 0.060 |
Why?
| | Pentacyclic Triterpenes | 1 | 2026 | 12 | 0.060 |
Why?
| | Up-Regulation | 2 | 2019 | 851 | 0.060 |
Why?
| | Computer Simulation | 2 | 2023 | 1025 | 0.060 |
Why?
| | Brain Chemistry | 2 | 2009 | 116 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2006 | 47 | 0.060 |
Why?
| | Prednisolone | 1 | 2006 | 66 | 0.060 |
Why?
| | Health Planning Guidelines | 1 | 2006 | 24 | 0.060 |
Why?
| | Solitary Nucleus | 1 | 2026 | 24 | 0.060 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2006 | 99 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 914 | 0.060 |
Why?
| | Culture | 1 | 2006 | 125 | 0.060 |
Why?
| | Australia | 1 | 2006 | 286 | 0.060 |
Why?
| | Self Administration | 1 | 2026 | 124 | 0.060 |
Why?
| | Bone Resorption | 1 | 2006 | 80 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 162 | 0.060 |
Why?
| | Alleles | 2 | 2019 | 879 | 0.060 |
Why?
| | Program Evaluation | 2 | 2007 | 948 | 0.060 |
Why?
| | Vagus Nerve | 1 | 2026 | 91 | 0.060 |
Why?
| | Muscle Fatigue | 1 | 2006 | 97 | 0.060 |
Why?
| | Spheroids, Cellular | 1 | 2026 | 73 | 0.060 |
Why?
| | HIV Infections | 1 | 2020 | 3154 | 0.060 |
Why?
| | Germ-Free Life | 1 | 2025 | 33 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 4154 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 405 | 0.050 |
Why?
| | Phosphorylation | 2 | 2019 | 1732 | 0.050 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 388 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2115 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2527 | 0.050 |
Why?
| | Health Promotion | 2 | 2008 | 774 | 0.050 |
Why?
| | Schools | 1 | 2008 | 453 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 201 | 0.050 |
Why?
| | Pregnancy | 4 | 2022 | 7190 | 0.050 |
Why?
| | Acetylation | 1 | 2024 | 252 | 0.050 |
Why?
| | Sports | 1 | 2006 | 211 | 0.050 |
Why?
| | Molecular Sequence Annotation | 1 | 2024 | 105 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 780 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2017 | 3604 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 1158 | 0.050 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2006 | 182 | 0.050 |
Why?
| | Albumins | 1 | 2023 | 118 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 2089 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2008 | 588 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 187 | 0.050 |
Why?
| | Trastuzumab | 1 | 2023 | 118 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3671 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 479 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 245 | 0.050 |
Why?
| | Microarray Analysis | 2 | 2015 | 117 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 558 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7990 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 974 | 0.040 |
Why?
| | Health Behavior | 1 | 2007 | 785 | 0.040 |
Why?
| | Epigenomics | 1 | 2022 | 114 | 0.040 |
Why?
| | Actins | 1 | 2024 | 425 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 588 | 0.040 |
Why?
| | Odds Ratio | 2 | 2020 | 1075 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 851 | 0.040 |
Why?
| | Mass Screening | 2 | 2010 | 1347 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1414 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2020 | 2155 | 0.040 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 103 | 0.040 |
Why?
| | Blotting, Western | 2 | 2015 | 1187 | 0.040 |
Why?
| | Iodine | 1 | 2021 | 26 | 0.040 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2004 | 467 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 62 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2017 | 11679 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2001 | 268 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2001 | 276 | 0.040 |
Why?
| | Curriculum | 1 | 2008 | 1059 | 0.040 |
Why?
| | Oxysterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Time Factors | 4 | 2019 | 7173 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2006 | 484 | 0.040 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2020 | 45 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 168 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 229 | 0.040 |
Why?
| | Kainic Acid | 1 | 2020 | 33 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2022 | 251 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 155 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2020 | 75 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2006 | 1720 | 0.040 |
Why?
| | DNA Primers | 1 | 2001 | 512 | 0.040 |
Why?
| | Indians, North American | 1 | 2006 | 647 | 0.040 |
Why?
| | Carbon | 1 | 2021 | 203 | 0.040 |
Why?
| | Catheterization | 1 | 2000 | 183 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 85 | 0.040 |
Why?
| | Protective Agents | 1 | 2019 | 42 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 68 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2022 | 6429 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 74 | 0.040 |
Why?
| | Metabolic Syndrome | 2 | 2017 | 354 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 153 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 86 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2019 | 160 | 0.040 |
Why?
| | Urinary Bladder Diseases | 1 | 2019 | 18 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 188 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2021 | 180 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 197 | 0.040 |
Why?
| | Emtricitabine | 1 | 2020 | 205 | 0.040 |
Why?
| | Sample Size | 1 | 2019 | 123 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 46 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 417 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 223 | 0.040 |
Why?
| | Sensation | 1 | 1999 | 55 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2020 | 106 | 0.040 |
Why?
| | Education | 1 | 2019 | 104 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1795 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 238 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 128 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 522 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 327 | 0.040 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 147 | 0.040 |
Why?
| | Normal Distribution | 1 | 2018 | 22 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2021 | 430 | 0.040 |
Why?
| | Ligaments | 1 | 2019 | 75 | 0.040 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 71 | 0.040 |
Why?
| | Protons | 1 | 2019 | 95 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 276 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 18 | 0.040 |
Why?
| | Sirtuins | 1 | 2019 | 50 | 0.040 |
Why?
| | Metyrapone | 1 | 2018 | 5 | 0.040 |
Why?
| | Neuroimaging | 1 | 2021 | 289 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 551 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 2020 | 147 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 19 | 0.030 |
Why?
| | Computer Graphics | 1 | 2018 | 41 | 0.030 |
Why?
| | Colorado | 3 | 2020 | 4564 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 329 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 2018 | 5 | 0.030 |
Why?
| | Analgesics | 1 | 2020 | 228 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 86 | 0.030 |
Why?
| | Sirtuin 3 | 1 | 2019 | 60 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2008 | 2168 | 0.030 |
Why?
| | Receptors, IgE | 1 | 2018 | 43 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 266 | 0.030 |
Why?
| | Uterus | 1 | 2019 | 226 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 180 | 0.030 |
Why?
| | Bacteria | 1 | 2025 | 889 | 0.030 |
Why?
| | Ribosomes | 1 | 2019 | 191 | 0.030 |
Why?
| | Abdominal Pain | 1 | 1999 | 146 | 0.030 |
Why?
| | Magnetite Nanoparticles | 1 | 2017 | 28 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 187 | 0.030 |
Why?
| | Thioredoxins | 1 | 2017 | 30 | 0.030 |
Why?
| | Azo Compounds | 1 | 2017 | 30 | 0.030 |
Why?
| | Organ Specificity | 1 | 2018 | 312 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2019 | 766 | 0.030 |
Why?
| | Crigler-Najjar Syndrome | 1 | 1997 | 2 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 76 | 0.030 |
Why?
| | Dronabinol | 1 | 2020 | 247 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 369 | 0.030 |
Why?
| | Heterozygote | 3 | 1994 | 315 | 0.030 |
Why?
| | Metal Nanoparticles | 1 | 2018 | 85 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 1997 | 18 | 0.030 |
Why?
| | Tuberculosis | 1 | 2020 | 291 | 0.030 |
Why?
| | Solubility | 2 | 2008 | 242 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1313 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 430 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1098 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 380 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 410 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 177 | 0.030 |
Why?
| | Medication Adherence | 1 | 2020 | 539 | 0.030 |
Why?
| | Exons | 2 | 1997 | 358 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2016 | 69 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2007 | 273 | 0.030 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 226 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 384 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 1030 | 0.030 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 708 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 98 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 529 | 0.030 |
Why?
| | Autophagy | 1 | 2018 | 286 | 0.030 |
Why?
| | Iopamidol | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2919 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 196 | 0.030 |
Why?
| | Animals, Inbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 760 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 710 | 0.030 |
Why?
| | Child | 4 | 2014 | 22633 | 0.030 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 19 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1337 | 0.030 |
Why?
| | Codon | 2 | 1992 | 94 | 0.030 |
Why?
| | Heart | 1 | 2018 | 636 | 0.030 |
Why?
| | Genetic Testing | 1 | 1997 | 478 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 854 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 893 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 197 | 0.030 |
Why?
| | Glutathione | 1 | 2016 | 375 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 389 | 0.030 |
Why?
| | Histones | 1 | 2019 | 669 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 402 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 481 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 436 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2834 | 0.030 |
Why?
| | Triglycerides | 1 | 2016 | 520 | 0.030 |
Why?
| | Saliva | 2 | 2006 | 249 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2015 | 192 | 0.030 |
Why?
| | Chelation Therapy | 1 | 2013 | 10 | 0.020 |
Why?
| | Iron Chelating Agents | 1 | 2013 | 18 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1813 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2882 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2017 | 737 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2182 | 0.020 |
Why?
| | Ovarian Diseases | 1 | 2012 | 13 | 0.020 |
Why?
| | Entropy | 1 | 2012 | 45 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2050 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1486 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2273 | 0.020 |
Why?
| | Thalassemia | 1 | 1992 | 6 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1047 | 0.020 |
Why?
| | Exome | 1 | 2013 | 227 | 0.020 |
Why?
| | Ultrasonography, Doppler | 1 | 2012 | 126 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6048 | 0.020 |
Why?
| | Data Mining | 1 | 2012 | 117 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2011 | 54 | 0.020 |
Why?
| | Transferrin | 1 | 2011 | 50 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.020 |
Why?
| | DNA | 3 | 1994 | 1463 | 0.020 |
Why?
| | Placenta | 1 | 2018 | 780 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1821 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 177 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 490 | 0.020 |
Why?
| | Genetics, Behavioral | 1 | 2010 | 17 | 0.020 |
Why?
| | Thermosensing | 1 | 2010 | 12 | 0.020 |
Why?
| | Ovary | 1 | 2012 | 228 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1244 | 0.020 |
Why?
| | Software Design | 1 | 2010 | 25 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2010 | 124 | 0.020 |
Why?
| | Obesity | 1 | 2004 | 3077 | 0.020 |
Why?
| | Neurons | 1 | 2020 | 1640 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 232 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 2011 | 121 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 91 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2010 | 102 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 300 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1993 | 370 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2009 | 10 | 0.020 |
Why?
| | Blood Proteins | 1 | 2011 | 249 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 10 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2010 | 91 | 0.020 |
Why?
| | Corticosterone | 1 | 2010 | 244 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 40 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2112 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2008 | 57 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1489 | 0.020 |
Why?
| | New Mexico | 1 | 2008 | 99 | 0.020 |
Why?
| | Social Marketing | 1 | 2008 | 16 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 251 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
| | Rural Health | 1 | 2008 | 87 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 174 | 0.020 |
Why?
| | Brain Mapping | 1 | 2010 | 536 | 0.020 |
Why?
| | Pituitary Function Tests | 1 | 2007 | 2 | 0.020 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2007 | 8 | 0.020 |
Why?
| | Sunlight | 1 | 2008 | 78 | 0.020 |
Why?
| | Fruit | 1 | 2008 | 152 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 395 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 170 | 0.020 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2006 | 23 | 0.020 |
Why?
| | Myoglobin | 1 | 2006 | 12 | 0.020 |
Why?
| | Acetaldehyde | 1 | 2006 | 17 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2006 | 29 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2007 | 71 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2007 | 77 | 0.020 |
Why?
| | Genetic Carrier Screening | 2 | 1997 | 32 | 0.020 |
Why?
| | Pituitary Gland | 1 | 2007 | 148 | 0.020 |
Why?
| | Reminder Systems | 1 | 2007 | 141 | 0.010 |
Why?
| | Electrophysiology | 1 | 2006 | 218 | 0.010 |
Why?
| | Osteoclasts | 1 | 2006 | 52 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2006 | 200 | 0.010 |
Why?
| | Hormones | 1 | 2006 | 134 | 0.010 |
Why?
| | Hip Prosthesis | 1 | 2006 | 42 | 0.010 |
Why?
| | Bone and Bones | 1 | 2008 | 314 | 0.010 |
Why?
| | Educational Status | 1 | 2008 | 467 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 269 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 214 | 0.010 |
Why?
| | Physical Endurance | 1 | 2006 | 278 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 302 | 0.010 |
Why?
| | Pedigree | 2 | 1997 | 514 | 0.010 |
Why?
| | Educational Measurement | 1 | 2008 | 326 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 61 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2004 | 88 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 333 | 0.010 |
Why?
| | Electromyography | 1 | 2006 | 415 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2004 | 223 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 200 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 151 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 842 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 437 | 0.010 |
Why?
| | Vitamin D | 1 | 2006 | 400 | 0.010 |
Why?
| | Dietary Fats | 1 | 2004 | 314 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5960 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1462 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 719 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2008 | 847 | 0.010 |
Why?
| | Viscera | 1 | 1999 | 17 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2006 | 885 | 0.010 |
Why?
| | Psychological Tests | 1 | 1999 | 132 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1135 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 3333 | 0.010 |
Why?
| | Pain Measurement | 1 | 2000 | 552 | 0.010 |
Why?
| | Cytokines | 1 | 2006 | 2061 | 0.010 |
Why?
| | Child, Preschool | 2 | 2008 | 11787 | 0.010 |
Why?
| | Perception | 1 | 2000 | 377 | 0.010 |
Why?
| | Genetics, Population | 1 | 1997 | 214 | 0.010 |
Why?
| | Prenatal Diagnosis | 1 | 1997 | 195 | 0.010 |
Why?
| | Registries | 1 | 2004 | 2385 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2438 | 0.010 |
Why?
| | Homozygote | 1 | 1994 | 199 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 1992 | 32 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 331 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1054 | 0.000 |
Why?
| | Infant | 1 | 1997 | 10034 | 0.000 |
Why?
|
|
Saba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|